The scientific abstract is published in the journal, *Anesthesia & Analgesia*, the official journal of the International Anesthesia Research Society that all members receive as a benefit of membership.

About the study: Senzime, in collaboration with the principal investigator Dr. J. Ross Renew, a recognized researcher in the area of neuromuscular pharmacology and physiology carried out a validation study in awake volunteers to evaluate TetraGraph’s ease of use, required set-up time, and the discomfort associated with neurostimulation. The TetraGraph was compared with the existing neuromuscular monitor that is based on acceleromyography, the TOF-Watch.

The conclusion of the abstract: The TetraGraph monitor is a hand-held electromyographic (EMG) medical device that delivers neurostimulation that is less painful than the TOF-Watch device in awake, healthy volunteers. The lower discomfort may be due to the larger stimulating area of the TetraGraph electrodes that decreases stimulating current density and therefore, the pain associated with neurostimulation. The investigators found the monitor easy to use, and required less than a minute for set-up and calibration. The investigators will begin exploring intraoperative applications of the monitor. [Link to the abstract.](#)

Every year over 70 million surgical patients undergo general anesthesia and receive neuromuscular blocking drugs. Without objective monitoring, over 30 percent of these patients experience postoperative complications. The TetraGraph monitor is a portable and user-friendly EMG-based device that allows quantitative neuromuscular monitoring in settings where motion detection (acceleromyography) is not possible.

Senzime will exhibit at stand #19 the meeting [http://www.iars.org/education/annual_meeting/](http://www.iars.org/education/annual_meeting/)

**Certified Adviser**
FNCA är Certified Adviser för Senzime.

**For further information, please contact:**
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com

**TO THE EDITORS**
**About Senzime**
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on Nasdaq First North (Ticker SEZI) [www.senzime.com](http://www.senzime.com)